Work

1048 Targeting the early ovarian cancer antigen ORF1p with an mRNA-LNP vaccine for cancer interception

Year: 2026
Type: conference-abstract
Abstract: Background Long interspersed nuclear element-1 (LINE-1) retrotransposons comprise approximately 20% of the human genome and encode two proteins, open reading frame proteins 1 and 2 (ORF1p and ORF2p) that mediate its retrotransposition via a ‘copy-and-paste’ mechanism across the genome. Due to its mutagenic potential, LINE-1 is normally epigenetically silenced in adult tissues but becomes aberrantly reactivated in many malignancies. We previously demonstrated that ORF1p is expressed in the earliest precursor lesions of high-grade serous ovarian cancer (HGSOC) and ovarian clear cell carcinoma (CCOC), indicating that LINE-1 activation is an early event in ovarian carcinogenesis. 1 2 Because ORF1p is tumor-associated, broadly expressed across patients, and present early in disease development, we hypothesized that it may serve as an attractive target for cancer interception and immunotherapy. We further postulated that an mRNA-lipid nanoparticle (LNP) vaccine strategy could elicit robust antigen-specific cellular immune responses capable of recognizing and eliminating ORF1p-expressing tumor cells.Methods Several syngeneic HGSOC lines and tumor nodules were evaluated for ORF1p expression. Murine ORF1p mRNA was generated in Drew Weissman’s Lab and packaged into lipid nanoparticles (LNPs) by Acuitas Therapeutics. In vitro expression following transfection in cell lines was confirmed by western blotting and immunocytochemistry. Six-week-old female FVB mice received a 10 μg intramuscular prime vaccination followed by a booster dose three weeks later. Five days after boosting, harvested splenocytes were restimulated with overlapping 15mer peptide pools and intracellular functional flow cytometry assays were used to evaluate immune responses elicited by our vaccine.Results Multiple syngeneic murine HGSOC models expressed ORF1p in vitro and maintained expression in vivo, supporting their future use in vaccination challenge studies. Using a prime-single boost vaccination strategy, we have consistently observed a strong CD4+ T cell response, with tumor necrosis factor (TNF) and interferon gamma (IFNγ) double positive effector memory CD4+ T cells exceeding responses generated by an equivalent ovalbumin control vaccination. In parallel, we detected a moderate but reproducible CD8α+ T cell response characterized by IFNγ+ and Granzyme B+ effector memory CD8+ T cells, supporting the induction of functional cytotoxic lymphocyte populations.Conclusions ORF1p mRNA-LNP vaccination generates durable antigen-specific cellular immune responses, including effector memory CD4 + and CD8+ T-cell populations. These findings support the development of ORF1p as a novel cancer vaccine target and provide a foundation for future optimization strategies aimed at enhancing cytotoxic responses and evaluating anti-tumor efficacy in syngeneic ovarian cancer challenge models.References Sato S, Gillette M, de Santiago PR, Kuhn E, Burgess M, Doucette K, Feng Y, Mendez-Dorantes C, Ippoliti PJ, Hobday S, Mitchell MA, Doberstein K, Gysler SM, Hirsch MS, Schwartz L, Birrer MJ, Skates SJ, Burns KH, Carr SA, Drapkin R. LINE-1 ORF1p as a candidate biomarker in high grade serous ovarian carcinoma. Sci Rep. 2023 Jan 27;13(1):1537. doi: 10.1038/s41598-023-28840-5. PMID: 36707610; PMCID: PMC9883229.de Santiago PR, Sato S, Zhang SJ, Dougher MC, Devins KM, Bilecz AJ, Rayamajhi S, Mingo G, Rendulich HS, Feng Y, Wu C, Taylor MS, Zhuravlev Y, Jung E, Omran DK, Wang TL, Shih IM, Schwartz LE, Kim S, Morgan MA, Tanyi JL, Burns KH, Lengyel E, Parra-Herran C, Godwin AK, Walt DR, Drapkin R. LINE-1 ORF1p expression occurs in clear cell ovarian carcinoma precursors and is a candidate blood biomarker. NPJ Precis Oncol. 2025 Mar 6;9(1):62. doi: 10.1038/s41698-025-00849-1. PMID: 40050409; PMCID: PMC11885553.Ethics Approval The study was approved by The University of Pennsylvania Institutional Animal Care and Use Committee (IACUC), protocol number 806138.
Language: English
Subfield: Immunology
Open Access status: gold
Estimated APC paid: $2,490
OpenAlex ID: W7225142323
Cites: 2
Cited by:
Related to: 10